Efficacy and Safety Evaluation of the Treatment of Allergy Against Cupressaceae and Grasses.
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Asthma, Allergic
- Rhinitis Allergic
- Rhinoconjunctivitis
- Type
- Interventional
- Phase
- Phase 3
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: Randomized, double-blind, placebo-controlled, multicentre, parallel-group studyMasking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)Masking Description: During the trial, both the investigator and the included subjects will be unaware of the treatment each subject is receiving. The person in charge of data analysis will also not know the treatment assigned to each subject until the database has been closed. So that neither the subject nor the investigator knows what treatment each subject is receiving, all the trial medication is identical in terms of outer packaging and appearance.Primary Purpose: Treatment
Participation Requirements
- Age
- Between 14 years and 65 years
- Gender
- Both males and females
Description
Double blind, multicenter, parallel, placebo controlled study. It includes 150 subjects sensitised to cupressaceae and grass pollen, from 14 to 65 years of age. Medication treatment during 1 year. The main outcome: CSMS
Double blind, multicenter, parallel, placebo controlled study. It includes 150 subjects sensitised to cupressaceae and grass pollen, from 14 to 65 years of age. Medication treatment during 1 year. The main outcome: CSMS
Tracking Information
- NCT #
- NCT04898283
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Pedro Carretero, MD Hospital Universitario de Burgos
Get Well Soon